Palantir Technologies Stock Takes a Hit After CEO Denies Surveillance Allegations Amid Investor Concerns

https://icaro.icaromediagroup.com/system/images/photos/16539017/original/open-uri20250606-18-1tq8ptg?1749196048
ICARO Media Group
News
06/06/2025 07h31

### Palantir Stock Plummets As CEO Refutes Allegations

Shares of Palantir Technologies (PLTR) experienced a sharp decline on Thursday, falling by 5.9% as of 2:48 p.m. ET. This drop occurred against the backdrop of a slight downturn in broader markets, with the S&P 500 dipping 0.2% and the Nasdaq Composite falling 0.4%.

The decline follows a recent report by The New York Times that highlighted Palantir's significant access to federal government data. This access, the report claimed, could potentially enhance President Donald Trump’s surveillance capabilities. As Palantir has developed its reputation for leveraging artificial intelligence to process massive data sets, the article suggested that the company's integration into federal operations could significantly impact its financial outcomes.

Initially, the report led to a surge in Palantir’s stock price as investors viewed the deepening ties with the government as a sign of robust growth potential. However, in a recent CNBC interview, CEO Alex Karp strongly denied one of the report's major claims, asserting that Palantir does not engage in the surveillance of American citizens. This rebuttal prompted apprehension among investors, resulting in the stock's downturn on Thursday.

Regardless of Karp's assurances, Palantir's relationship with the federal government remains extensive and appears to be strengthening. However, concerns about the company's valuation persist. With a price-to-earnings ratio (P/E) of 560, many believe that Palantir's current valuation is excessively high and disconnected from realistic growth expectations. Critics argue that while Palantir is undoubtedly performing well, such a steep valuation necessitates flawless execution to be justified.

The mixed reactions to Palantir's recent developments underscore the tension between ethical considerations and investor optimism regarding the company’s future prospects.

The views expressed in this article do not reflect the opinion of ICARO, or any of its affiliates.

Related